内容概要：人工硬脑膜是用生物材料制成人体脑膜的替代物，用于因颅脑、脊髓损伤、肿瘤及其他颅脑 疾病引起的硬脑膜或脊膜缺损的修补，防止脑脊液外漏、颅内感染、脑膨出、脑粘连和疤痕等严重并发 症，以恢复其完整性。人工硬脑膜属于植介入耗材，伴随着国民可支配收入增加、老龄化程度加深，脑 血管疾病发病率上升，神经外科介入类手术需求增加，推动人工硬脑膜的需求放量增长。但2021年以来 随着集采的稳步推进，国内人工硬脑膜产品价格下降较为明显。2024年，我国人工硬脑膜需求量从2017 年的44.63万片增长至94.61万片，产品价格从2017年的1775元/片下降至800元/片，人工硬脑膜市场规模 则从2020年的10.26亿元下降至2024年的7.57亿元。 关键词：人工硬脑膜行业政策、人工硬脑膜产业链、人工硬脑膜需求量、人工硬脑膜行业均价、人工硬 脑膜市场规模、人工硬脑膜市场竞争格局、人工硬脑膜行业发展趋势 一、人工硬脑膜行业基本概况 神经外科作为医学领域最为复杂的学科之一，是以手术为主要手段，医治中枢神经系统（脑、脊髓）、 周围神经系统和植物神经系统疾病的一门临床外科专科。作为高精尖的前沿学科之一，神经外科对应用 在手术 ...

Group 1 - The latest stock price of Maipu Medical is 80.19 yuan, an increase of 0.89 yuan from the previous trading day [1] - The opening price was 79.36 yuan, with a highest point of 80.79 yuan and a lowest point of 77.04 yuan, and the trading volume reached 12,446 hands with a transaction amount of 0.98 billion yuan [1] - On August 28, around 13:15, Maipu Medical experienced a rapid rebound, with a price increase of over 2% within 5 minutes, rising from 78.74 yuan to 79.21 yuan, and the transaction amount during this period was 46.14 million yuan with a turnover rate of 1.05% [1] Group 2 - Maipu Medical operates in the medical device industry, focusing on the research and production of implantable medical devices in neurosurgery and dentistry [1] - The company is recognized as a high-tech enterprise, with a product line that includes artificial dura mater and craniofacial repair systems among other medical consumables [1] Group 3 - In terms of capital flow, Maipu Medical saw a net outflow of 5.62 million yuan on that day, with a cumulative net outflow of 24.14 million yuan over the past five trading days [1]

Group 1 - The stock price of Maipu Medical experienced fluctuations on August 19, closing at 85.68 yuan, down 1.29% from the previous trading day [1] - The trading volume on that day was 12,560 hands, with a transaction amount of 1.09 billion yuan, and a price fluctuation of 5.28% [1] - Maipu Medical operates in the medical device industry, focusing on the research and production of implantable medical devices in neurosurgery and oral fields, with products including artificial dura mater and craniofacial repair systems [1] Group 2 - On August 18, the company announced that shareholder Guoshou Chengda completed a reduction plan, selling a total of 1.9956 million shares, accounting for 2.9958% of the company's total share capital [1] - After the reduction, Guoshou Chengda's shareholding ratio decreased to 1.9093% [1] - On August 19, the net inflow of main funds was 6.2331 million yuan, representing 0.13% of the circulating market value, while the cumulative net outflow over the past five trading days was 3.0485 million yuan, accounting for 0.06% of the circulating market value [1]